Merck's shot, called Capvaxive, specifically protects against 21 strains of that bacteria to prevent a severe form of pneumococcal disease that can spread to other parts of the body and lead to ...

Merck’s new 21-valent pneumococcal conjugate vaccine, Capvaxive, and pulmonary arterial hypertension drug, Winrevair, have the potential to generate significant revenues for Merck over the long ...

With Capvaxive, MSD (known as Merck & Co in the US and Canada) is aiming to carve out a niche in the over-50s, positioning it as the go-to vaccine used to prevent invasive pneumococcal disease ...

Following FDA approval, CAPVAXIVE was unanimously recommended by the CDC’s Advisory Committee on Immunization Practices for pneumococcal vaccination for certain adults. In addition, Merck ...

In recent months, Merck has made notable strides in expanding its product offerings. The company received FDA approval for CAPVAXIVE, a 21-valent pneumococcal conjugate vaccine (PCV) for adults ...

Merck MRK also markets two PCV vaccines — Capvaxive and Vaxneuvance. MRK received FDA approval for Vaxneuvance in 2021 for 15 serotypes in older adults. Merck generated $647 million from ...

Merck's vaccine portfolio continues to be a key driver of growth and stability for the company. The recent FDA approval of CAPVAXIVE, a 21-valent pneumococcal conjugate vaccine (PCV) for adults, has ...

In recent months, Merck has made notable strides in expanding its product offerings. The company received FDA approval for CAPVAXIVE, a 21-valent pneumococcal conjugate vaccine (PCV) for adults, ...